Syndecan-4 Enhances Therapeutic Angiogenesis after Hind Limb Ischemia in Mice with Type 2 Diabetes

Subhamoy Das, Anthony J. Monteforte, Gunjan Singh, Marjan Majid, Michael B. Sherman, Andrew K. Dunn, Aaron B. Baker

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

Delivering syndecan-4 with FGF-2 improves the effectiveness of FGF-2 therapy for ischemia in the diabetic disease state. The syndecan-4 proteoliposomes significantly enhance in vitro tubule formation as well as blood perfusion and vessel density in the ischemic hind limbs of diseased ob/ob mice. Syndecan-4 therapy also induces a marked immunomodulation in the tissues, increasing the polarization of macrophages toward the M2 phenotype.

Original languageEnglish (US)
Pages (from-to)1008-1013
Number of pages6
JournalAdvanced Healthcare Materials
Volume5
Issue number9
DOIs
StatePublished - May 11 2016
Externally publishedYes

Keywords

  • Fibroblast growth factor-2 (FGF-2)
  • Ischemia
  • Peripheral vascular diseases
  • Syndecan-4
  • Therapeutic angiogenesis

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Syndecan-4 Enhances Therapeutic Angiogenesis after Hind Limb Ischemia in Mice with Type 2 Diabetes'. Together they form a unique fingerprint.

Cite this